Achieve Life Sciences Inc(QUIT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.38 | Insider Own | 32.16% | Shs Outstand | 109.8M | Perf Week | -12.03% |
| Market Cap | 0.58B | Forward P/E | - | EPS next Y | 44.58% | Insider Trans | -0.06% | Shs Float | 69.8M | Perf Month | -14.46% |
| Enterprise Value | 0.39B | PEG | - | EPS next Q | -0.2 | Inst Own | 66.07% | Short Float | 25.97% | Perf Quarter | -29.97% |
| Income | -0.11B | P/S | - | EPS this Y | -6.69% | Inst Trans | 54.21% | Short Ratio | 13.24 | Perf Half Y | 18.55% |
| Sales | 0.00B | P/B | 3.38 | EPS next 5Y | - | ROA | -86.44% | Short Interest | 18.13M | Perf YTD | 11.87% |
| Book/sh | 1.65 | P/C | 2.86 | EPS past 3/5Y | 32.06% 25.38% | ROE | -104.23% | 52W High | -35.65% ($8.64) | Perf Year | 43.3% |
| Cash/sh | 1.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -59.73% | 52W Low | 112.21% ($2.62) | Perf 3Y | 0.91% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -0.17% | Gross Margin | - | Volatility(W/M) | 5.76% 6.46% | Perf 5Y | -27.23% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.4 | Perf 10Y | -99.48% |
| Dividend Ex-Date | - | Quick Ratio | 10.49 | EPS Q/Q | 59.45% | Profit Margin | - | RSI (14) | 31.46 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.49 | Sales Q/Q | - | SMA20 | -14.15% ($6.48) | Beta | 2.42 | Target Price | $13.75 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/11/10 | SMA50 | -20.11% ($6.96) | Rel Volume | 1.41 | Prev Close | $5.87 |
| Employees | 28 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 44.92% - | SMA200 | -3.36% ($5.75) | Avg Volume(3M) | 1.37M | Price | $5.56 |
| IPO | 1995/10/12 | Option/Short | Yes/Yes | Trades | 10509 | Volume | 1,926,879 | Change | -5.28% |
🚭 A US-based late-stage clinical pharmaceutical company developing treatments for nicotine dependence. The company is developing cytisine, a plant-derived alkaloid compound, for two indications: smoking cessation and electronic cigarette withdrawal, and is conducting late-stage clinical trials and regulatory processes aiming for US FDA approval. Recently, the company has rebranded as AchieveRx and is focusing on preparations for commercialization.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
Traded more than usual. That is 141% of its average volume.
QUIT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -6.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -27.2%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
It ranks #191 of 598 in the industry
Based on market cap of $577M.
FAQ
QUIT belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of QUIT is approximately $577M, ranking 2,907 within its sector.
QUIT has recorded a 52-week high of $8.64 and a low of $2.62.